Patients with
previously untreated non-
squamous NSCLC or NSCLC not otherwise
classified
|
Histological diagnosis of
non- squamous NSCLC or
NSCLC not otherwise classified
|
EGFR gene mutation testing
and, after presenting with locally advanced
or metastatic disease, use of first-line erlotinib in patients with
tumours expressing EGFR exon 19 deletions or exon 21 point
mutation L858R and use of platinum-based doublet
chemotherapy in patients not expressing these EGFR gene
mutations and in those patients whose EGFR gene mutation status is unknown
|
Primary comparator
No EGFR gene mutation testing and use of
treatment with platinum- based doublet chemotherapy after presenting with locally
advanced or metastatic disease
|
No agreed reference standard currently
available, but comparisons should be made against the
specific tests used to generate the evidence to support the effectiveness of first-
line erlotinib (the
“evidentiary”
standard), specifically:
PCR followed by length analysis in an
ABI Prism 3130 DNA
analyser for exon 19 deletions and a 5’
nuclease PCR (Taqman) assay for exon 21 point
mutations (EURTAC
trial)
PCR-based direct sequencing
(OPTIMAL trial)
|
|
